DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3203-291-294$20.00
DMD 32:291-294, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nozawa, T.
Right arrow Articles by Tamai, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nozawa, T.
Right arrow Articles by Tamai, I.
SHORT COMMUNICATION

INVOLVEMENT OF ORGANIC ANION TRANSPORTING POLYPEPTIDES IN THE TRANSPORT OF TROGLITAZONE SULFATE: IMPLICATIONS FOR UNDERSTANDING TROGLITAZONE HEPATOTOXICITY

Takashi Nozawa, Shigeki Sugiura, Miki Nakajima, Akihiko Goto, Tsuyoshi Yokoi, Jun-Ichi Nezu, Akira Tsuji, and Ikumi Tamai

Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan (T.N., A.G., I.T.); Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (T.N., M.N., T.Y., A.T.) Medical Genetics Research Center, Nara Medical University, Nara, Japan (S.S.) Chugai Pharmaceutical Co. Ltd., Ibaraki, Japan (J.-I.N.)

Troglitazone is a thiazolidinedione insulin sensitizer drug that is metabolized mainly to a sulfate conjugate (M-1) in humans. It was reported to cause hepatotoxicity, although the cause has not been fully clarified. The objective of this study was to identify whether organic anion transporting polypeptide (OATP) transporters expressed at the basolateral membrane of human hepatocytes participate in troglitazone-associated hepatotoxicity. When OATP-B, OATP-C, or OATP8 was expressed in Xenopus oocytes, the transporter-mediated uptake into oocytes of troglitazone sulfate conjugate and the inhibitory effects of thiazolidinediones and the metabolites of troglitazone on estrone-3-sulfate transport were measured. M-1 was transported well by OATP-C but was not transported by OATP-B. OATP8 showed weak, but not statistically significant, transport of M-1. M-1 exhibited a strong inhibitory effect on estrone-3-sulfate transport by OATP-C and OATP8, suggesting a higher affinity than other thiazolidinediones and the metabolites of troglitazone, glucuronide conjugate and quinone metabolite. In conclusion, the sulfate conjugate of troglitazone has a higher affinity for OATPs than troglitazone itself or other metabolites. Since OATP transporters are important in the hepatic handling of bile acids, bilirubin, and other endogenous anionic compounds, M-1 may disturb the hepatic influx and efflux transport of these endogenous molecules across the basolateral membranes. Moreover, OATP-C may be involved in the hepatic toxicity of troglitazone through the inhibitory action of M-1.


Address correspondence to: Dr. Ikumi Tamai, Department of Molecular Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. E-mail: tamai{at}rs.noda.tus.ac.jp




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Grime, P. J. H. Webborn, and R. J. Riley
Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes
Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
I. Bachmakov, H. Glaeser, M. F. Fromm, and J. Konig
Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1
Diabetes, June 1, 2008; 57(6): 1463 - 1469.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Enokizono, H. Kusuhara, and Y. Sugiyama
Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect
Drug Metab. Dispos., February 1, 2007; 35(2): 209 - 214.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
X. Cheng, J. Maher, M. Z. Dieter, and C. D. Klaassen
REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDES (OATPS) IN LIVER BY PROTOTYPICAL MICROSOMAL ENZYME INDUCERS THAT ACTIVATE DISTINCT TRANSCRIPTION FACTOR PATHWAYS
Drug Metab. Dispos., September 1, 2005; 33(9): 1276 - 1282.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Chang, K. S. Pang, P. W. Swaan, and S. Ekins
Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 533 - 541.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
D. C. Kemp, M. J. Zamek-Gliszczynski, and K. L. R. Brouwer
Xenobiotics Inhibit Hepatic Uptake and Biliary Excretion of Taurocholate in Rat Hepatocytes
Toxicol. Sci., February 1, 2005; 83(2): 207 - 214.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Nozawa, M. Suzuki, K. Takahashi, H. Yabuuchi, T. Maeda, A. Tsuji, and I. Tamai
Involvement of Estrone-3-Sulfate Transporters in Proliferation of Hormone-Dependent Breast Cancer Cells
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1032 - 1037.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. He, R. E. Talaat, W. F. Pool, M. D. Reily, J. E. Reed, A. J. Bridges, and T. F. Woolf
METABOLIC ACTIVATION OF TROGLITAZONE: IDENTIFICATION OF A REACTIVE METABOLITE AND MECHANISMS INVOLVED
Drug Metab. Dispos., June 1, 2004; 32(6): 639 - 646.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.